A Phase 1 interventional study of Microneedle Patch and Patch with no microneedles in Topical Anaesthesia, sponsored by Innoture Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-14.
Sponsored by Innoture Ltd · Phase 1, Interventional, and Treatment
To look at the effect on patient perceived pain resulting from infiltration injection with local anaesthetic in a dental syringe with prior application of topical anaesthetic to the oral mucosa on a microneedle patch compared to a patch with no microneedles. To look at the safety of the patches when applied to the oral mucosa.
This is a randomised, 2 treatment, double blind design, with respect to the clinical assessor and subject, split mouth, crossover design with a negative control (patch with no microneedles).
Potential participants will be invited to attend a screening visit. At this visit participants will be asked to read and sign a Participant Information Sheet and Consent Form prior to any study procedures being performed. They will be given ample time to decide if they wish to participate in the study.
A dentally qualified clinician will record the participant's demographics, medical history, current/concomitant medications, perform an oral soft tissue examination and ensure the participant fulfils the inclusion and exclusion criteria for the study. Two areas of the mouth will be identified for assessment during the study. The areas of the mouth will be identified as S1 or S2. Site S1 will be left or right palatal mucosa adjacent to the premolar area and S2 will be left or right upper buccal mucosa adjacent to the upper lateral incisor area.
Participants who successfully fulfil all the necessary entrance criteria will be provided with training by study staff on how to use a VAS record sheet and randomised on to the study to receive treatment combination A or B at in a random order according to a predetermined randomisation schedule supplied by the study statistician. The screening visit and first treatment visit will occur at the same visit. The treatment possibilities are outlined below:
Treatment A The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
Treatment B The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
The chosen sites will be: S1; left and right palatal mucosa adjacent to the premolar area or S2; left and right upper buccal mucosa adjacent to the upper lateral incisor area. Each participant at the first visit will have either S1 or S2 sites allocated for treatment. For example, Treatment A will be allocated to S1 left side and Treatment B to S1 right side or vice versa. At the second visit, 2 weeks (+/- 3 days) after the first visit, Treatment B will be allocated to S2 left side and Treatment A to S2 right side. Both sides of the mouth for S1 or S2 will be treated at the same. After each treatment participants will be asked to make pain assessments relating to needle insertion into the oral mucosa and the giving of the local infiltration anaesthetic.
It is envisaged that a sufficient number of potential participants will be screened in order to randomise 16 onto the study.
Assessment methods: Pain assessments will be performed after application of the topical anaesthetic for 3 minutes. Each test will be performed sequentially i.e. 3 separate needle insertions, with pain assessments recorded by the participant using a Visual Analogue Scale (VAS) and a verbal pain grading after each test. The level of pain at S1 or S2 will be assessed as follows:
Test I. A short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, will be used to penetrate the oral mucosa at the treated site and the patient asked to score the pain using a VAS rating scale and by verbal grading of zero, mild, moderate or severe.
Test 2. The same needle will be inserted through the oral mucosa and down to contact bone. Pain will be assessed as in Test 1.
Test 3. The same needle will be again inserted through the oral mucosa and the cartridge of local anaesthetic will be injected into the site. Pain will be again assessed as in Test I.
Following enrolment on to the study, participants will be given written and verbal instructions on the VAS and how to complete it.
This is the only study on the registry with Innoture Ltd as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
Device: Microneedle Patch
The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
Device: Patch with no microneedles
At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
VAS in Healthy Participants, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia.
Pain levels were recorded using a visual analogue scale (VAS). When responding to the VAS item, subjects were required to indicate their level of pain by indicating a position along a continuous line between two end-points of no pain (0) and worst pain imaginable (100). The lower the score the better the outcome. The topical lidocaine was applied either with a microneedle patch or a patch with no microneedles for 3 minutes. Immediately afterwards three tests were performed: Test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site; test 2, the same needle was inserted through the oral mucosa and down to contact bone; test 3, the same needle was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.
Time frame: Following 3 minutes of application of topical anaesthetic using a patch, the 3 tests were performed and the pain score recorded immediately after each test.
Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel is Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 1
Pain levels will be recorded using a Verbal Pain Grading. For the verbal pain grading, subjects are asked to score either zero, mild, moderate or severe. In test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site.
Time frame: Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.
Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 2
Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 2, the same needle as test 1 was inserted through the oral mucosa and down to contact bone.
Time frame: Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.
Verbal Pain Grading, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a Patch With No Microneedle Patch, Prior to Infiltration With Local Anaesthesia. Test 3
Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 3, the same needle as test 1 and test 2 was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.
Time frame: Following three minutes of application of topical anaesthetic with a patch, the 3 tests were performed and the pain score recorded immediately after each test.
Adverse Events in Healthy Participants When a Proprietary Topical 5% Lidocaine Dental Gel Was Applied to the Oral Mucosa With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia.
Adverse events were recorded
Time frame: Events were collected from the time of informed consent until end of treatment or when an ongoing AE had resolved whichever was latest, unless the PI & the Innoture contact from the clinical investigation plan agreed that no further follow up was needed.
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 3 | 4 | 4 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
Pain levels were recorded using a visual analogue scale (VAS). When responding to the VAS item, subjects were required to indicate their level of pain by indicating a position along a continuous line between two end-points of no pain (0) and worst pain imaginable (100). The lower the score the better the outcome. The topical lidocaine was applied either with a microneedle patch or a patch with no microneedles for 3 minutes. Immediately afterwards three tests were performed: Test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site; test 2, the same needle was inserted through the oral mucosa and down to contact bone; test 3, the same needle was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.
| units on a scale | Treatment A - Microneedle Patch, Palatal | Treatment B - Patch With no Microneedles, Palatal | Treatment A - Microneedle Patch, Buccal | Treatment B - Patch With no Microneedles, Buccal |
|---|---|---|---|---|
| VAS scores, test 1 | 5.1 ± 5.8 | 12.3 ± 11.6 | 0.7 ± 1.0 | 4.0 ± 5.8 |
| VAS scores, test 2 | 11.9 ± 11.3 | 18.7 ± 12.4 | 2.8 ± 4.0 | 6.9 ± 6.6 |
| VAS scores, test 3 | 26.8 ± 20.1 | 39.5 ± 25.1 | 18.3 ± 17.5 | 30.6 ± 20.7 |
Pain levels will be recorded using a Verbal Pain Grading. For the verbal pain grading, subjects are asked to score either zero, mild, moderate or severe. In test 1, a short dental needle, mounted on a dental syringe containing a cartridge of 2% lidocaine hydrochloride and 1:80,000 adrenaline, was used to penetrate the oral mucosa at the treated site.
| Participants | Treatment A - Microneedle Patch, Palatal | Treatment B - Patch With no Microneedles, Palatal | Treatment A - Microneedle Patch, Buccal | Treatment B - Patch With no Microneedles, Buccal |
|---|---|---|---|---|
| Verbal Pain Grading, Test 1- Zero | 8 | 5 | 15 | 13 |
| Verbal Pain Grading, Test 1 - Mild | 8 | 8 | 0 | 2 |
| Verbal Pain Grading, Test 1 - Moderate | 0 | 3 | 0 | 0 |
| Verbal Pain Grading, Test 1 - Severe | 0 | 0 | 0 | 0 |
Adverse events were recorded
| Events | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 |
|---|---|---|---|---|
| Adverse Events in Healthy Participants When a Proprietary Topical 5% Lidocaine Dental Gel Was Applied to the Oral Mucosa With a Microneedle Patch and a Patch With no Microneedles, Prior to Infiltration With Local Anaesthesia. | 0 | 0 | 0 | 0 |
Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 2, the same needle as test 1 was inserted through the oral mucosa and down to contact bone.
| Participants | Treatment A - Microneedle Patch, Palatal | Treatment B - Patch With no Microneedles, Palatal | Treatment A - Microneedle Patch, Buccal | Treatment B - Patch With no Microneedles, Buccal |
|---|---|---|---|---|
| Verbal Pain Grading, Test 2 - Zero | 8 | 3 | 14 | 11 |
| Verbal Pain Grading, Test 2 - Mild | 5 | 9 | 1 | 4 |
| Verbal Pain Grading, Test 2 - Moderate | 3 | 4 | 0 | 0 |
| Verbal Pain Grading, Test 2 - Severe | 0 | 0 | 0 | 0 |
Pain levels were recorded using a Verbal Pain Grading. For the verbal pain grading, subjects were asked to score either zero, mild, moderate or severe. In test 3, the same needle as test 1 and test 2 was again inserted through the oral mucosa and the cartridge of local anaesthetic was injected into the site.
| Participants | Treatment A - Microneedle Patch, Palatal | Treatment B - Patch With no Microneedles, Palatal | Treatment A - Microneedle Patch, Buccal | Treatment B - Patch With no Microneedles, Buccal |
|---|---|---|---|---|
| Verbal Pain Grading, Test 3 - Zero | 1 | 1 | 3 | 1 |
| Verbal Pain Grading, Test 3 - Mild | 7 | 3 | 8 | 7 |
| Verbal Pain Grading, Test 3 - Moderate | 8 | 10 | 4 | 7 |
| Verbal Pain Grading, Test 3 - Severe | 0 | 2 | 0 | 0 |
Collected over Adverse events were collected from the time of informed consent until end of treatment or when an ongoing AE had resolved whichever was latest, unless the PI and the Innoture contact named in the clinical investigation plan agreed that no further follow up was necessary.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Group 1 | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Treatment Group 2 | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Treatment Group 3 | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Treatment Group 4 | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 16 |
| >=65 years | 0 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 31.4 (18.9 to 57.0) |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 6 |
| Male | 10 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Study Participants |
|---|---|
| United Kingdom | 16 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.